Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to $298.8 million.

  • Amicus Therapeutics' Shares Outstanding (Weighted Average) rose 3.93% to $308.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.2 million, marking a year-over-year increase of 3.93%. This contributed to the annual value of $298.8 million for FY2024, which is 1.90% up from last year.
  • Amicus Therapeutics' Shares Outstanding (Weighted Average) amounted to $298.8 million in FY2024, which was up 1.90% from $293.2 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' Shares Outstanding (Weighted Average) registered a high of $298.8 million during FY2024, and its lowest value of $260.6 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $293.2 million (2023), whereas its average is $291.0 million.
  • Data for Amicus Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 6.93% (in 2021) over the last 5 years.
  • Amicus Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $260.6 million in 2020, then climbed by 6.93% to $278.6 million in 2021, then climbed by 0.83% to $280.9 million in 2022, then grew by 4.38% to $293.2 million in 2023, then increased by 1.90% to $298.8 million in 2024.